Measurement of Adherence and Health-Related Quality of Life, and Health-Care Resource Utilization
- Conditions
- Cancer-related Venous Thromboembolism
- Interventions
- Behavioral: Questionnaires
- Registration Number
- NCT03407469
- Lead Sponsor
- M.D. Anderson Cancer Center
- Brief Summary
The goal of this research study is to learn about the quality of life, experiences with treatment, and healthcare costs of patients who are receiving long-term treatment for venous thromboembolism (VTE) that is related to cancer.
This is an investigational study. Up to 260 participants will be enrolled in this multicenter study. Up to 170 will take part in MD Anderson.
- Detailed Description
If you agree to take part in this study, you will complete 2 questionnaires either at an already-scheduled clinic visit or over the phone at the time you join this study and then about 30 days, 3 months, 6 months, and 12 months after that. These questionnaires will be about your quality of life and experiences with treatment for VTE. It should take less than 10 minutes to complete the questionnaires each time.
Information from your medical record may also be collected at these time points.
Your participation will be over after the last questionnaires are completed at about 12 months after you enroll in the study.
Recruitment & Eligibility
- Status
- RECRUITING
- Sex
- All
- Target Recruitment
- 260
- Adult (≥ 18 years) female or male subjects.
- Confirmed symptomatic proximal or distal lower extremity deep venous thrombosis with or without pulmonary embolism or other venous thromboses. For a symptomatic lower extremity deep venous thrombosis confirmed by compression ultrasonography, venography, or specific computerized tomography (CT) venography, or a thrombus detected in the iliac veins on an abdominal or pelvic CT. For symptomatic pulmonary embolism confirmed by computerized tomographic pulmonary angiography, ventilation perfusion scan, or catheter pulmonary angiography.
- Cancer (other than basal-cell or squamous-cell carcinoma of the skin), either active or diagnosed within 2 years prior to VTE. The diagnosis of cancer must be objectively documented by histopathologic diagnosis.
- Intention for long-term treatment (at least 3 months) with anticoagulation.
- Participants will be enrolled in the study within the first 72 hours from initiation of anticoagulation.
- Able to provide informed consent and complete study survey tools
- Able to read and speak English.
- Indication for anticoagulation other than cancer-related VTE.
- An Eastern Cooperative Oncology Group (ECOG) Performance Status of 4 at the time of study enrollment.
- Life expectancy < 3 months.
- Isolated pulmonary embolism, or isolated upper extremity deep venous thrombosis, or isolated splanchnic venous thrombosis, or isolated cerebral venous thrombosis confirmed by compression ultrasonography, venography, or CT.
Study & Design
- Study Type
- OBSERVATIONAL
- Study Design
- Not specified
- Arm && Interventions
Group Intervention Description Questionnaires Questionnaires Questionnaires completed at the time participant joins this study and then about 30 days, 3 months, 6 months, and 12 months after that. Questionnaires will be about quality of life and experiences with treatment for venous thromboembolism (VTE).
- Primary Outcome Measures
Name Time Method Self-Reported Adherence to Anticoagulation Baseline up to 6 months Adherence categorized as "adequate" versus "non-adequate" based on the Morisky scale.
- Secondary Outcome Measures
Name Time Method HRQL Variables in Patients for Cancer-Related VTE Treated with Anticoagulation Baseline, 3 months, and 6 months The HRQL variables measured using a deep venous thrombosis quality of life questionnaire: DVTQOL.
Trial Locations
- Locations (4)
Hospital Clinic
🇪🇸Barcelona, Carrer De Villarroel, 170, Spain
Fundacion Valle del Lili
🇨🇴Cali, Colombia
Hospital German Trias i Pujol
🇪🇸Barcelona,, Spain
University of Texas MD Anderson Cancer Center
🇺🇸Houston, Texas, United States